MarketCap
Facebook
X
TelegramAnnual report 2022
added 03-31-2023
Ayala Pharmaceuticals DSO Ratio 2011-2026 | AYLA
Annual DSO Ratio Ayala Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 61.7 | 35.4 | 67 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 67 | 35.4 | 54.7 |
Quarterly DSO Ratio Ayala Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 196 | 1.08 K | 63.6 | - | 95 | 65.8 | 39.8 | - | 94.4 | 59.5 | 52.4 | - | 50.6 | 50.2 | 80.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.08 K | 39.8 | 161 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
132 | $ 215.54 | -1.16 % | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
103 | $ 3.88 | -1.27 % | $ 415 M | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
70.9 | $ 19.23 | - | $ 899 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
239 | $ 8.18 | -2.97 % | $ 109 M | USA |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
2.47 | - | - | $ 546 M | USA |
 |
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | USA |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
9.68 | $ 0.71 | 17.15 % | $ 8.13 M |  Israel |
 |
CytomX Therapeutics
CTMX
|
12.3 | $ 4.24 | -4.83 % | $ 585 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
81.5 K | - | -5.98 % | $ 34.1 M | USA |
 |
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | USA |
 |
Genmab A/S
GMAB
|
97.9 | $ 25.81 | 0.51 % | $ 16.6 B | Danmark |
 |
Aytu BioScience
AYTU
|
150 | $ 2.65 | 0.76 % | $ 16.6 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
56.5 | - | - | $ 2.02 B | USA |
 |
BioDelivery Sciences International
BDSI
|
115 | - | -4.8 % | $ 255 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Eton Pharmaceuticals
ETON
|
39.1 | $ 22.97 | -3.53 % | $ 618 M | USA |
 |
Exelixis
EXEL
|
43.4 | $ 41.57 | 0.39 % | $ 11.3 B | USA |
 |
Fortress Biotech
FBIO
|
80.5 | $ 2.92 | -2.01 % | $ 60.7 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
50 | $ 4.31 | -2.49 % | $ 826 M | Canada |